Chemomab Therapeutics Ltd.
CMMB
$1.23
$0.000.00%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -- | 7.08M | 9.07M | 11.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | 25.46M | 30.25M | 32.26M |
| Operating Income | -- | -- | -25.46M | -30.25M | -32.26M |
| Income Before Tax | -- | -- | -24.22M | -29.07M | -31.81M |
| Income Tax Expenses | -- | -- | 0.00 | 10.00K | -513.00K |
| Earnings from Continuing Operations | -- | -- | -24.22 | -29.08 | -31.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -24.22M | -29.08M | -31.30M |
| EBIT | -- | -- | -25.46M | -30.25M | -32.26M |
| EBITDA | -- | -- | -25.39M | -30.19M | -32.20M |
| EPS Basic | -- | -- | -42.38 | -51.81 | -55.51 |
| Normalized Basic EPS | -- | -- | -1.11 | -1.40 | -1.76 |
| EPS Diluted | -- | -- | -42.38 | -51.81 | -55.51 |
| Normalized Diluted EPS | -- | -- | -1.11 | -1.40 | -1.76 |
| Average Basic Shares Outstanding | -- | -- | 46.97M | 45.22M | 45.16M |
| Average Diluted Shares Outstanding | -- | -- | 2.35M | 2.26M | 2.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |